JPWO2022023447A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022023447A5 JPWO2022023447A5 JP2023505743A JP2023505743A JPWO2022023447A5 JP WO2022023447 A5 JPWO2022023447 A5 JP WO2022023447A5 JP 2023505743 A JP2023505743 A JP 2023505743A JP 2023505743 A JP2023505743 A JP 2023505743A JP WO2022023447 A5 JPWO2022023447 A5 JP WO2022023447A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- unsubstituted
- compound
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 47
- 125000000217 alkyl group Chemical group 0.000 claims 30
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 15
- 125000001072 heteroaryl group Chemical group 0.000 claims 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 14
- 125000000623 heterocyclic group Chemical group 0.000 claims 13
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 12
- 229910052799 carbon Inorganic materials 0.000 claims 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- -1 s - butyl Chemical group 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 125000003107 substituted aryl group Chemical group 0.000 claims 8
- 125000004429 atom Chemical group 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 125000004452 carbocyclyl group Chemical group 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 208000025997 central nervous system neoplasm Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 150000003852 triazoles Chemical class 0.000 claims 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000029862 Barrett adenocarcinoma Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims 1
- 208000036566 Erythroleukaemia Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 1
- 201000007286 Pilocytic astrocytoma Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 201000005746 Pituitary adenoma Diseases 0.000 claims 1
- 206010061538 Pituitary tumour benign Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 claims 1
- 102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000005969 Uveal melanoma Diseases 0.000 claims 1
- 208000021841 acute erythroid leukemia Diseases 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 230000001740 anti-invasion Effects 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000010989 colorectal carcinoma Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000021310 pituitary gland adenoma Diseases 0.000 claims 1
- 150000003217 pyrazoles Chemical class 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 108010077182 raf Kinases Proteins 0.000 claims 1
- 102000009929 raf Kinases Human genes 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 208000000649 small cell carcinoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 238000002626 targeted therapy Methods 0.000 claims 1
- 150000003527 tetrahydropyrans Chemical class 0.000 claims 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063057536P | 2020-07-28 | 2020-07-28 | |
| US63/057,536 | 2020-07-28 | ||
| PCT/EP2021/071212 WO2022023447A2 (en) | 2020-07-28 | 2021-07-28 | Fused bicyclic raf inhibitors and methods for use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023535790A JP2023535790A (ja) | 2023-08-21 |
| JP2023535790A5 JP2023535790A5 (https=) | 2024-08-06 |
| JPWO2022023447A5 true JPWO2022023447A5 (https=) | 2024-08-06 |
Family
ID=77499800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023505743A Pending JP2023535790A (ja) | 2020-07-28 | 2021-07-28 | 縮合二環式ｒａｆ阻害薬及びその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11858930B2 (https=) |
| EP (1) | EP4188552A2 (https=) |
| JP (1) | JP2023535790A (https=) |
| KR (1) | KR20230058399A (https=) |
| CN (1) | CN116601150A (https=) |
| AU (1) | AU2021314955A1 (https=) |
| BR (1) | BR112023001557A2 (https=) |
| CA (1) | CA3187514A1 (https=) |
| IL (1) | IL300113A (https=) |
| MX (1) | MX2023001275A (https=) |
| WO (1) | WO2022023447A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023535790A (ja) | 2020-07-28 | 2023-08-21 | ジャズ ファーマシューティカルズ アイルランド リミテッド | 縮合二環式ｒａｆ阻害薬及びその使用方法 |
| CN116143633A (zh) * | 2022-12-30 | 2023-05-23 | 浙江巍华新材料股份有限公司 | 一种制备2,5-二氯-4-三氟甲基苯胺的方法 |
| EP4665725A2 (en) * | 2023-02-17 | 2025-12-24 | Jazz Pharmaceuticals Ireland Limited | Methods of treating solid tumors with mitogen activated protein kinase (mapk) pathway alterations |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3932657A (en) | 1973-11-12 | 1976-01-13 | The United States Of America As Represented By The United States Energy Research And Development Administration | Liposome encapsulation of chelating agents |
| GB1575343A (en) | 1977-05-10 | 1980-09-17 | Ici Ltd | Method for preparing liposome compositions containing biologically active compounds |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4452747A (en) | 1982-03-22 | 1984-06-05 | Klaus Gersonde | Method of and arrangement for producing lipid vesicles |
| JPS6058915A (ja) | 1983-09-12 | 1985-04-05 | Fujisawa Pharmaceut Co Ltd | 薬物含有脂質小胞体製剤 |
| US4744989A (en) | 1984-02-08 | 1988-05-17 | E. R. Squibb & Sons, Inc. | Method of preparing liposomes and products produced thereby |
| US5736155A (en) | 1984-08-08 | 1998-04-07 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| US5077056A (en) | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| US4830858A (en) | 1985-02-11 | 1989-05-16 | E. R. Squibb & Sons, Inc. | Spray-drying method for preparing liposomes and products produced thereby |
| US4921757A (en) | 1985-04-26 | 1990-05-01 | Massachusetts Institute Of Technology | System for delayed and pulsed release of biologically active substances |
| JPH0617309B2 (ja) | 1985-11-29 | 1994-03-09 | 株式会社ビタミン研究所 | アドリアマイシン包埋リポソ−ム製剤 |
| DE3611229A1 (de) | 1986-04-04 | 1987-10-08 | Basf Ag | Verfahren zur herstellung von feinverteilten, pulverfoermigen carotinoidpraeparaten |
| MX9203808A (es) | 1987-03-05 | 1992-07-01 | Liposome Co Inc | Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos. |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5766635A (en) | 1991-06-28 | 1998-06-16 | Rhone-Poulenc Rorer S.A. | Process for preparing nanoparticles |
| US5698550A (en) | 1993-06-14 | 1997-12-16 | Pfizer Inc. | Tetralin and chroman derivatives useful in the treatment of asthma, arthritis and related diseases |
| DE69529054T2 (de) | 1994-02-28 | 2003-08-21 | Nanopharm Ag | System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung |
| US5800833A (en) | 1995-02-27 | 1998-09-01 | University Of British Columbia | Method for loading lipid vesicles |
| EP0825852B1 (en) | 1995-04-18 | 2004-07-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposome drug-loading method and composition |
| US6465445B1 (en) | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
| US8137699B2 (en) | 2002-03-29 | 2012-03-20 | Trustees Of Princeton University | Process and apparatuses for preparing nanoparticle compositions with amphiphilic copolymers and their use |
| FI20011507A0 (fi) | 2001-07-10 | 2001-07-10 | Orion Corp | Uusia yhdisteitä |
| US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| CA2462376C (en) | 2001-10-03 | 2010-12-14 | Celator Technologies Inc. | Liposome loading with metal ions |
| CA2467064C (en) | 2001-11-13 | 2011-02-08 | Murray Webb | Lipid carrier compositions with enhanced blood stability |
| FI20030030A0 (fi) | 2003-01-09 | 2003-01-09 | Orion Corp | Uusia yhdisteitä |
| CN1690056A (zh) | 2004-04-30 | 2005-11-02 | 北京大学 | 三个化合物及其制备方法和用途 |
| GB0503506D0 (en) | 2005-02-21 | 2005-03-30 | 4 Aza Bioscience Nv | Substituted pyrido(2,3-d) pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders |
| WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| CN101365682A (zh) | 2005-12-08 | 2009-02-11 | 千禧药品公司 | 具有激酶抑制活性的双环化合物 |
| WO2008009079A2 (en) | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | Substituted pteridines useful for the treatment and prevention of viral infections |
| EP2167497A2 (en) * | 2007-06-29 | 2010-03-31 | Sunesis Pharmaceuticals, Inc. | Heterocyclic compounds useful as raf kinase inhibitors |
| US9273046B2 (en) | 2011-12-31 | 2016-03-01 | Beigene, Ltd. | Fused tricyclic compounds as Raf kinase inhibitors |
| GB201416186D0 (en) | 2014-09-12 | 2014-10-29 | Redx Pharma Ltd | Compounds |
| CN109503659B (zh) | 2019-01-03 | 2021-06-18 | 凯特立斯（深圳）科技有限公司 | 氧杂螺环双膦配体及其在α,β-不饱和羧酸不对称氢化中的应用 |
| JP2023535790A (ja) | 2020-07-28 | 2023-08-21 | ジャズ ファーマシューティカルズ アイルランド リミテッド | 縮合二環式ｒａｆ阻害薬及びその使用方法 |
| WO2022023450A1 (en) | 2020-07-28 | 2022-02-03 | Jazz Pharmaceuticals Ireland Limited | Chiral synthesis of fused bicyclic raf inhibitors |
-
2021
- 2021-07-28 JP JP2023505743A patent/JP2023535790A/ja active Pending
- 2021-07-28 CN CN202180066002.9A patent/CN116601150A/zh active Pending
- 2021-07-28 CA CA3187514A patent/CA3187514A1/en active Pending
- 2021-07-28 KR KR1020237006991A patent/KR20230058399A/ko active Pending
- 2021-07-28 US US17/387,049 patent/US11858930B2/en active Active
- 2021-07-28 WO PCT/EP2021/071212 patent/WO2022023447A2/en not_active Ceased
- 2021-07-28 IL IL300113A patent/IL300113A/en unknown
- 2021-07-28 BR BR112023001557A patent/BR112023001557A2/pt unknown
- 2021-07-28 EP EP21759247.6A patent/EP4188552A2/en active Pending
- 2021-07-28 AU AU2021314955A patent/AU2021314955A1/en active Pending
- 2021-07-28 MX MX2023001275A patent/MX2023001275A/es unknown
-
2023
- 2023-11-16 US US18/511,344 patent/US12304912B2/en active Active
-
2025
- 2025-05-12 US US19/205,876 patent/US20260092063A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2606497C2 (ru) | Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ | |
| JP2009543771A5 (https=) | ||
| JP2008528467A5 (https=) | ||
| JP2016513660A5 (https=) | ||
| JP2020503299A5 (https=) | ||
| CN102203075B (zh) | 二环激酶抑制剂 | |
| CN114430739A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| DK2197878T3 (en) | FORMATIONS OF kinase inhibitors AND USE THEREOF FOR THE TREATMENT OF CANCER AND OTHER DISEASES RELATED TO kinases | |
| JP2019503385A5 (https=) | ||
| JP2021514359A5 (https=) | ||
| CN107548391A (zh) | 嘧啶或吡啶类化合物、其制备方法和医药用途 | |
| JP2018532737A5 (https=) | ||
| JP2019535744A5 (https=) | ||
| RU2010150786A (ru) | Пирролопиридины как ингибиторы киназы | |
| JP2019535746A5 (https=) | ||
| EP3880676A1 (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
| RU2014153627A (ru) | Имидазо[1, 2-]пиридазиновые производные как ингибиторы киназ | |
| JP2018048121A (ja) | キナーゼ阻害剤としての新規環置換ｎ−ピリジニルアミド | |
| JP2011506402A5 (https=) | ||
| JP6896701B2 (ja) | イミダゾリルアミド誘導体 | |
| JP2014518544A5 (https=) | ||
| RU2011139352A (ru) | Замещенные пиридазин-карбоксамидные соединения в качестве соединений, ингибирующих киназы | |
| JP2021523168A5 (https=) | ||
| JPWO2020165833A5 (https=) | ||
| TW202313048A (zh) | 組合療法 |